2-(1-ethyl-4-piperidinyl)ethanol | 1208367-88-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-(1-ethyl-4-piperidinyl)ethanol
• 英文别名: 2-(1-Ethylpiperidin-4-yl)ethan-1-ol；2-(1-ethylpiperidin-4-yl)ethanol
• CAS: 1208367-88-7
• 化学式: C₉H₁₉NO
• 分子量: 157.256
• InChiKey: PXAVRWJOPPIPBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(1-ethyl-4-piperidinyl)ethanol 、 3-(哌啶-4-基)丙烷-1-醇盐酸盐 生成 3-(1-ethyl-4-piperidinyl)-1-propanol
  参考文献：
  名称：

  Adenine derivatives

  摘要：

  本发明涉及公式（I）的化合物：其中R1为C1-6烷基氨基或C1-6烷氧基；R2是具有结构的基团：n为1至6的整数；Het是含有一个氮原子的6元饱和杂环，其中Het连接到杂环的任何碳原子处于—（CH2）n—基团上；R3为氢、C1-8烷基或C3-7环烷基C0-6烷基；以及其盐是人类干扰素的诱导剂。诱导人类干扰素的化合物可以用于治疗各种疾病，例如过敏性疾病和其他炎症性疾病，例如过敏性鼻炎和哮喘，感染性疾病和癌症的治疗，也可以作为疫苗佐剂有用。

  公开号：

  US08563717B2
• 作为产物：
  描述：

  4-哌啶乙醇 、 碘乙烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 2-(1-ethyl-4-piperidinyl)ethanol
  参考文献：
  名称：

  [EN] NOVEL ADENINE DERIVATIVES
  [FR] NOUVEAUX DÉRIVÉS D'ADÉNINE

  摘要：

  式(I)的化合物中，其中R1是C1-6烷基氨基或C1-6烷氧基；R2是具有结构(II)的基团：n是一个值为1至6的整数；Het是一个含有一个氮原子的6元饱和杂环，其中Het连接到杂环的任何碳原子上的-(CH2)n-基团；R3是氢、C1-8烷基或C3-7环烷基C0-6烷基；以及其盐是人干扰素的诱导剂。诱导人干扰素的化合物可能在治疗各种疾病中有用，例如治疗过敏性疾病和其他炎症性疾病，例如过敏性鼻炎和哮喘，治疗传染性疾病和癌症，并且还可能作为疫苗佐剂有用。

  公开号：

  WO2010018134A1

文献信息

• JAK INHIBITOR
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2108642A1

  公开（公告）日：2009-10-14

  A JAK inhibitor comprising, as an active ingredient, a nitrogen-containing heterocyclic compound represented by formula (I) wherein W represents a nitrogen atom or -CH-; X represents -C (=O) - or -CHR4- (wherein R4 represents a hydrogen atom, or the like); R1 represents the formula described below [wherein Q1 represents-CR8-(wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); Q2 represents -NR15- (wherein R15 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); and R5 and R6 may be the same or different and each represents a hydrogen atom, halogen, carboxy, substituted or unsubstituted lower alkyl, or the like], or the like; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof.

  一种JAK抑制剂，其作为活性成分的是由式(I)表示的含氮杂环化合物 其中W代表氮原子或-CH-; X代表-C(=O)-或-CHR4-(其中R4代表氢原子或类似物); R1代表下述式[其中Q1代表-CR8-(其中R8代表氢原子、取代或未取代的较低烷基或类似物); Q2代表-NR15-(其中R15代表氢原子、取代或未取代的较低烷基或类似物);而R5和R6可以相同也可以不同，每个代表氢原子、卤素、羧基、取代或未取代的较低烷基或类似物，或类似物;而 R2和R3可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的较低烷基或类似物}或其药学上可接受的盐。
• Cinnoline compounds
  申请人：——

  公开号：US20030212055A1

  公开（公告）日：2003-11-13

  The invention relatest to compounds of the formula (I) wherein either any one of G 1 , G 2 , G 3 , G 4 and G 5 is nitrogen and the other four are —CH—, or G 1 , G 2 , G 3 , G 4 and G 5 are all —CH—; Z is —O—, —NH—, —S—, —CH 2 — or a direct bond; Z is linked to any one of G 1 , G 2 , G 3 and G 4 which is a free carbon atom; n is an integer from 0 to 5; any of the substitutents R 1 may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 3; R a represents hydrogen; R b represents hydrogen or another value as defined herein; R 1 represents hydrogen, oxo, hydroxy, halogeno, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy, C 1-4 -alkyl, aminoC 1-4 alkyl, C 1-3 alkylaminoC 1-4 alkyl, di(C 1-3 alkyl)aminoC 1-4 alkyl, —C 1-5 alkyl(ring B) wherein ring B is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-methylpiperazinly, N-ethylpiperazinyl, morpholino and thiomorpholino; R 2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 aklylsulphanyl, —NR 3 R 4 (wherein R 3 and R 4 , which may be the same or different, each represents hydrogen or C 1-3 alkyl), or R 5 X 1 — (wherein R 5 and X 1 are as defined herein) and salts thereof, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  该发明涉及以下式(I)的化合物，其中G1、G2、G3、G4和G5中的任何一个是氮，其他四个是—CH—，或者G1、G2、G3、G4和G5都是—CH—；Z是—O—、—NH—、—S—、—CH2—或直接键；Z与G1、G2、G3和G4中的任何一个自由碳原子相连；n是从0到5的整数；R1的任何取代基可能连接到吲哚、氮杂吲哚或吲唑基团的任何自由碳原子；m是从0到3的整数；Ra代表氢；Rb代表氢或本文中定义的另一个值；R1代表氢、氧代、羟基、卤代、C1-4烷基、C1-4烷氧基、C1-4烷氧基、C1-4烷基、氨基C1-4烷基、C1-3烷基氨基C1-4烷基、二(C1-3烷基)氨基C1-4烷基、—C1-5烷基(环B)，其中环B选自氮杂环丙烷基、吡咯烷基、哌啶基、哌嗪基、N-甲基哌嗪基、N-乙基哌嗪基、吗啉和硫代吗啉；R2代表氢、羟基、卤代、氰基、硝基、三氟甲基、C1-3烷基、C1-3烷氧基、C1-3烷基硫基、—NR3R4(其中R3和R4，可能相同也可能不同，各自代表氢或C1-3烷基)，或R5X1—(其中R5和X1如本文所定义)及其盐，制备这类化合物的方法，含有式I的化合物或其药学上可接受的盐作为活性成分的药物组合物，以及利用式I的化合物制备药物，用于在温血动物中产生抗血管生成和/或血管通透性降低作用。式I的化合物及其药学上可接受的盐抑制VEGF的作用，这是治疗多种疾病状态的有价值特性，包括癌症和类风湿性关节炎。
• Quinoline derivatives having vegf inhibiting activity
  申请人：——

  公开号：US20030199491A1

  公开（公告）日：2003-10-23

  The invention relates to compounds of formula (I) wherein: either any one of G 1 , G 2 , G 3 , G 4 and G 5 is nitrogen and the other four are —CH—, or G 1 , G 2 , G 3 , G 4 and G 5 are all —CH—; Z is —O—, —NH—, —S—, —CH 2 — or a direct bond; Z is linked to any one of G 1 , G 2 , G 3 and G 4 ; n is an integer from 0 to 5; m is an integer from 0 to 3; R a represents hydrogen or fluoro; R b , R 1 and R 2 are defined herein and salt thereof, process for the preparation so such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of a medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blodded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of diseases states including cancer and rheumatoid arthritis.

  该发明涉及以下式（I）的化合物：其中：G1、G2、G3、G4和G5中的任意一个是氮，其他四个是—CH—，或者G1、G2、G3、G4和G5都是—CH—；Z是—O—、—NH—、—S—、—CH2—或直接键；Z与G1、G2、G3和G4中的任意一个相连；n是从0到5的整数；m是从0到3的整数；R代表氢或氟；Rb、R1和R2在此处定义，并且其盐，制备这种化合物的方法，含有式I的化合物或其药学上可接受的盐作为活性成分的药物组合物，以及利用式I的化合物制造用于在温血动物中产生抗血管生成和/或血管通透性降低作用的药物的用途。式I的化合物及其药学上可接受的盐抑制VEGF的作用，这是治疗多种疾病状态的有价值的特性，包括癌症和类风湿性关节炎。
• INHIBITORS OF C-FMS KINASE
  申请人：Illig Carl R.

  公开号：US20070249649A1

  公开（公告）日：2007-10-25

  The invention is directed to compounds of Formula I: wherein Z, X, J, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  该发明涉及以下式I的化合物：其中Z、X、J、R2和W如规范中所述，以及其溶剂合物、水合物、互变异构体和药用可接受的盐，这些化合物抑制蛋白酪氨酸激酶，特别是c-fms激酶。提供了治疗自身免疫疾病的方法；以及具有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、结肠癌、胃癌、毛细胞白血病和非小细胞肺癌的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经源性疼痛；以及骨质疏松症、Paget病和其他骨吸收导致发病率的疾病，包括关节炎、假体失败、破骨性肉瘤、骨髓瘤和肿瘤转移至骨骼的方法，使用式I的化合物也提供了。
• Chemical compounds
  申请人：——

  公开号：US20030207878A1

  公开（公告）日：2003-11-06

  The invention relates to compounds of the formula (I): wherein: ring C is 9 or 10-membered bicyclic heteroaromatic group containing at least one nitrogen atom in the ring attached to Z and optionally containing a further 1-3 heteroatoms, selected independently from O, S, and N, with the proviso that ring C is not a quinazoline, quinoline or cinnoline group; either any one of G 1 , G 2 , G 3 , G 4 and G 5 is nitrogen and the other four are —CH—; or G 1 , G 2 , G 3 , G 4 and G 5 are all —CH—; Z is —O—, NH—, —S—, CH 2 — or a direct substituents R 1 may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 2; R b represents hydrogen or another value as defined herein; R 1 represents hydrogen, hydroxy, halogeno, C 1-4 alkyl, or any other value as defined herein; R 2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylsulphanyl, —NR 3 R 4 (wherein R 3 and R 4 , which may be the same or different, each represents hydrogen or C 1-3 alkyl), or R 5 X 1 — (wherein R 5 and X 1 are as defined herein) and salts thereof, processes for the preparation of such compounds, pharmaceutical compositions

  本发明涉及具有以下化学式（I）的化合物：其中：环C是9或10元杂环脂环芳烃基团，至少含有一个氮原子连接到Z，并可选地含有另外1-3个杂原子，独立选择自O、S和N，条件是环C不是喹唑啉、喹啉或茴香啉基团；G1、G2、G3、G4和G5中的任何一个是氮，其他四个是—CH—；或者G1、G2、G3、G4和G5都是—CH—；Z是—O—、NH—、—S—、CH2—或直接取代基，R1可以连接到吲哚、氮杂吲哚或吲唑基团的任何自由碳原子处；m是0到2的整数；Rb代表氢或本文中定义的另一个值；R1代表氢、羟基、卤代基、C1-4烷基或本文中定义的任何其他值；R2代表氢、羟基、卤代基、氰基、硝基、三氟甲基、C1-3烷基、C1-3烷氧基、C1-3烷基硫基、—NR3R4（其中R3和R4，可能相同也可能不同，各自代表氢或C1-3烷基），或R5X1—（其中R5和X1如本文所定义），以及其盐，以及制备此类化合物的方法，制备药物组合物。